Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Unigene Platform Leads to Clinical Trial | Contract Pharma

What are you searching for?

Sign in

Unigene Platform Leads to Clinical Trial

Cara uses Peptelligence to advance CR845 formulation

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cara Therapeutics, a client of Unigene Laboratories, has commenced a Phase I study of its oral proprietary peptide-based, investigational drug, CR845, a novel peripherally-acting kappa opioid agonist in healthy volunteers. The CR845 oral capsules were formulated using Unigene’s validated, proprietary peptide manufacturing technology under a Manufacturing and Clinical Supply Agreement established in May 2011.

Ashleigh Palmer, Unigene’s president and chief executive officer, commented, “The commencement of Cara’s Phase I study of CR845 is the first clinical study initiated as a result of launching our new strategy a year ago and further validates our mission to deploy Peptelligence into as many oral peptide development programs as possible. With seven feasibility studies ongoing or completed, we believe we are well positioned to build a diverse portfolio of highly targeted project proposals from which we plan to generate near-term revenue from feasibility studies and service fees, while establishing a solid foundation for the potential of licensing agreements with high-value milestones and royalties.”

“Initiation of this trial represents an important advancement in the clinical potential of CR845 and will provide the basis for developing the drug beyond the treatment of acute pain in a hospital setting,” said Frederique Menzaghi, vice president of R&D at Cara Therapeutics. “There remains a significant unmet need among chronic pain patients for an effective analgesic without the debilitating or dangerous side-effects of currently used narcotic analgesics and NSAIDs. We believe that an oral formulation of CR845 has the potential to provide an effective and safer option for the treatment of chronic pain.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics